Project & Orders
Immunotherapy is emerging as a highly promising approach for the treatment of cancer. T cells (T lymphocytes), the armed forces of our immune system, constantly look for foreign antigens and discriminate abnormal (cancer or infected cells) from normal cells. Genetically modifying T cells with Chimeric Antigen Receptors (CAR)s is the most common approach to generate tumor-specific T cells. CAR-T cells targeting tumor-associated antigens can be infused into patients and attack the tumor.
ProMab Biotechnologies has developed many CAR-T products based on 15 years' experience on hybridomas, monoclonal antibodies (rabbit, mouse, and human), recombinant proteins, and cancer stem cells. ProMab's new custom CAR-T service is designed to take advantage of the astonishing clinical breakthroughs of CAR-T cells against various hematological malignancies.
ProMab Biotechnologies can construct CARs based on your antibody sequence or can generate a mouse or fully human single-chain variable fragment (scFv) for the CARs. PrMab has generated more than 25 types of CAR-T cells (and CAR-NK cells) targeting different tumor cells and cell lines expressing tumor-specific antigens. These CAR-T cells can be used with immunological modulators, tumor microenviroment invaders, or checkpoint inhibitors. In addition, ProMab has developed sensitive real-time cytotoxicity assays (RTCA) for CAR-T cell validation in vitro and ex vivo. ProMab has also developed in vivo NSG/ NOG xenograft models to test CAR-T cell anti-cancer activity in hematological and solid cancers.
Most Popular Service Plans And Prices